In HNSCC, in the group receiving palliative chemotherapy, patients with PD (progressive disease) showed significantly high expressions of 14 lncRNAs compared to patients with DCR (disease control rate, CR+PR+SD), 7SK (p = 0.0142), CAR Intergenic 10 (p = 0.0022), HAR1A (p = 0.0279), NOR (p = 0.0171), IGF2AS (p = 0.017), Kcnq1ot1 (p = 0.0316), KRASP1 (p = 0.0171), L1PA16 (p = 0.0266), LOC285194 (p = 0.0374), MEG (p = 0.0012), NTT (p = 0.0192), Zeb2NAT (p = 0.0112), SAF (p = 0.0494), and SNHG6 (p = 0.0494), as shown in Figure 5. This evidence concerns the gene ZEB2-AS1 and head and neck squamous cell carcinoma.